Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301715 | 0.95 | TUBB1 (0.36) | TUBB1NFE2L2APPERN1ALDH1A1 | |
| SCHEMBL10301712 | 0.90 | TUBB1 (0.39) | TUBB1NFE2L2ERN1 | |
| SCHEMBL12734720 | 0.88 | NFE2L2 (0.38) | TUBB1NFE2L2APP | |
| SCHEMBL10301704 | 0.87 | S1PR1 (0.39) | TUBB1NFE2L2APPALDH1A1MAPT | |
| SCHEMBL10301705 | 0.86 | TUBB1 (0.37) | TUBB1NFE2L2APPALDH1A1MAPT | |
| SCHEMBL10301703 | 0.85 | TUBB1 (0.43) | TUBB1NFE2L2ERN1 | |
| SCHEMBL10301710 | 0.85 | S1PR1 (0.38) | TUBB1APPALDH1A1MAPTMAPK1 | |
| SCHEMBL10301711 | 0.85 | S1PR1 (0.38) | TUBB1APPALDH1A1MAPTMAPK1 | |
| SCHEMBL10301683 | 0.85 | APP (0.30) | APP | |
| SCHEMBL10302907 | 0.85 | APP (0.32) | TUBB1APPERN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | TUBB1 548/4885NFE2L2 1646/4885APP 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.